EpiBone – a leading regenerative medicine company focused on skeletal repair – announced the closing of a convertible note funding round led by Kendall Capital Partners, with participation from LifeSpan Vision Ventures, EMV Capital, and others. This funding will propel EpiBone’s ongoing pipeline development, furthering its mission to revolutionize skeletal reconstruction on a global scale.
EpiBone’s technologies represent advanced treatment modalities that utilize autologous and allogeneic stem cells, 3D bioprinting, and bioreactor technology to provide personalized, effective solutions for bone and osteochondral reconstruction. And EpiBone stands on the frontier of regenerative medicine and seeks to disrupt the standard in musculoskeletal treatments.
KEY QUOTES:
“We are thrilled to have the continued support of Kendall Capital Partners, along with LifeSpan Vision Ventures, EMV Capital plc, and other strategic investors, who share our vision of transforming skeletal repair through groundbreaking science. This funding not only affirms the progress we’ve made but also empowers us to bring our innovative regenerative therapies to more patients in need as we explore Thailand and the United Arab Emirates, both emerging global centers of medical tourism.”
– Dr. Nina Tandon CEO and Co-Founder of EpiBone
“We are proud to lead a syndicate of institutional and strategic investors and family offices in this funding round to support EpiBone’s mission to revolutionize skeletal repair. Thinking globally from the outset is essential for cutting-edge technologies like EpiBone’s, as it accelerates commercialization and amplifies the scale of impact. EpiBone’s innovative approach is poised to transform the landscape of regenerative medicine, and we are thrilled to be part of their journey.”
– David Zhu, Founding Partner of Kendall Capital Partners
“EpiBone is revolutionizing healthcare with their cutting-edge approach to personalized medicine, offering a solution that not only has the potential to improve patients’ lives but also redefine how we treat complex diseases. They are developing technology that will shape the future of healthcare and we are proud to continue to support this visionary team as they enter the exciting next chapter of growth and innovation.”
– Dr. Ilian Iliev, CEO of EMV Capital
